# Rezdiffra authorised in the UK for adults with MASH and moderate-to-advanced liver scarring

Canonical page: https://technooptimist.io/stories/rezdiffra-authorised-in-the-uk-for-adults-with-mash-and-moderate-to-5cfa6eb4
Date: 3 Jun 2026
About: [Madrigal Pharmaceuticals](https://technooptimist.io/companies/madrigal-pharmaceuticals.md) · [Rezdiffra](https://technooptimist.io/biotech/rezdiffra.md)
Original source: https://medicalupdateonline.com/2026/06/rezdiffra-authorised-by-mhra-for-adults-with-mash-and-moderate-to-advanced-liver-fibrosis-madrigal-pharmaceuticals/

The UK medicines regulator (MHRA) authorised Madrigal's Rezdiffra (resmetirom) on 3 June 2026 for adults with MASH and stage 2 or 3 liver fibrosis. It used the International Recognition Procedure, which relies on the earlier EU decision. The approval does not settle NHS funding, which still has to be negotiated.

## Key facts

- Authorised strengths: 60 mg, 80 mg and 100 mg oral tablets; the basis is the EU conditional approval of August 2025.
- The main study enrolled 917 adults with MASH and moderate or advanced fibrosis and ran 12 months against placebo.
- MASH resolution with no fibrosis worsening: about 26–30% on resmetirom vs 10% on placebo, depending on dose.
- Fibrosis improvement with no MASH worsening: 27–29% on resmetirom vs 17% on placebo.
- Approval is not reimbursement: NHS coverage requires separate negotiation, not yet reported.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.